Biotech · Private company · San Francisco, CA, US

89bio, Inc.

SEC CIK 0001785173

Track this companyFree. Adds 89bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials50 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline3

PegozaferminPhase 3 · Severe HypertriglyceridemiaClinicalTrials.gov · fetched Nov 12, 2026
BIO89-100Phase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
PegozaferminPhase 2 · NASHClinicalTrials.gov · fetched Nov 12, 2026

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe HypertriglyceridemiaPHASE3 · COMPLETED · started Jun 15, 2023ClinicalTrials.gov NCT05852431 · fetched Nov 12, 2026
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation CirrhosisPHASE1 · COMPLETED · started Aug 16, 2021ClinicalTrials.gov NCT05022693 · fetched Nov 12, 2026
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Jun 4, 2021ClinicalTrials.gov NCT04929483 · fetched Nov 12, 2026
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe HypertriglyceridemiaPHASE2 · COMPLETED · started Sep 1, 2020ClinicalTrials.gov NCT04541186 · fetched Nov 12, 2026
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHPHASE1_PHASE2 · COMPLETED · started Jul 29, 2019ClinicalTrials.gov NCT04048135 · fetched Nov 12, 2026